Since the May 2022 Mpox outbreak began, people have been lining up to receive a smallpox vaccine authorized by the U.S. Food and Drug Administration (FDA).
Since then, numerous studies have been conducted to quantify if Bavarian Nordic's JYNNEOS® (MVA-BN) vaccine is effective in reducing virus transmission or hospitalizations against the mpox West African clade IIb subtype.
Can Mpox Vaccines Reduce Transmission or Hospitalization
In Situ, Invasive Melanoma Diagnoses Decreased in 2020
Significant decrease seen in incidence of stage I melanomas but not other stages
Cannabis Legalization, Commercialization Linked to Traffic Injuries
Threefold increase reported in quarterly rate of cannabis-involved traffic injury ED visits during commercialization
FDA Approval of New COVID-19 Boosters Could Come by Friday
The new booster targets the XBB.1.5 omicron subvariant, which is similar to the dominant variant now circulating